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A B S T R A C T
Cell-free transcription-translation systems were originally applied towards in vitro protein production. More
recently, synthetic biology is enabling these systems to be used within a systematic design context for
prototyping DNA regulatory elements, genetic logic circuits and biosynthetic pathways. The Gram-positive soil
bacterium, Bacillus subtilis, is an established model organism of industrial importance. To this end, we
developed several B. subtilis-based cell-free systems. Our improved B. subtilis WB800N-based system was
capable of producing 0.8 µM GFP, which gave a ~72x fold-improvement when compared with a B. subtilis 168
cell-free system. Our improved system was applied towards the prototyping of a B. subtilis promoter library in
which we engineered several promoters, derived from the wild-type Pgrac (σA) promoter, that display a range
of comparable in vitro and in vivo transcriptional activities. Additionally, we demonstrate the cell-free
characterisation of an inducible expression system, and the activity of a model enzyme - renilla luciferase.
1. Introduction
Cell-free systems that are based on cellular extracts were originally
developed as experimental systems to understand fundamental aspects
of molecular biology, cellular biochemistry and for in vitro protein
production (Hodgman and Jewett, 2012; Nirenberg, 2004; Sullivan
et al., 2016; Zubay, 1973). Synthetic biology approaches are enabling
the re-purposing of cell-free systems as coupled in vitro transcription–
translation characterisation platforms for the prototyping of DNA
based parts, devices and systems (Kelwick et al., 2014). Cell-free
transcription-translation systems have been employed to rapidly pro-
totype DNA regulatory elements (Chappell et al., 2013), logic systems
(Niederholtmeyer et al., 2015; Shin and Noireaux, 2012; Sun et al.,
2014; Takahashi et al., 2015) and medical biosensor devices (Pardee
et al., 2014) with workﬂows that can be completed within several
hours. In contrast, typical in vivo approaches may take several days.
Another distinguishing advantage of cell-free systems is that they can
be coupled with model-guided design strategies to create ‘biomolecu-
lar-breadboards’ that enable the robust cell-free characterisation of
bioparts that can then be implemented as ﬁnal designs in vivo (Siegal-
Gaskins et al., 2014). These developments are also enabling cell-free
protein synthesis driven metabolic engineering approaches for the
biochemical characterisation of novel enzymes and prototyping of
biosynthetic pathways (Karim and Jewett, 2016).
Several cell-free systems have been developed, of which, the most
well established systems use cellular extracts from Escherichia coli
(Garamella et al., 2016), Wheat Germ (Ogawa et al., 2016), Yeast (Gan
and Jewett, 2014) or HeLa cells (Gagoski et al., 2016). Additionally,
more specialist cell-free systems including the PURE express system,
which uses puriﬁed cellular machinery rather than cellular extracts,
have also been established (Shimizu et al., 2005). Whilst these cell-free
systems have been continually improved through developments in the
methods used for their preparation (Shrestha et al., 2012) and
optimisation of energy buﬀers (Caschera and Noireaux, 2015a,
2014), there have been fewer reports of Bacillus subtilis cell-free
systems. Yet, the development of robust B. subtilis cell-free systems
could have applicability to a broad array of microbiology, synthetic
biology and industrial biotechnology applications. Applications for B.
subtilis are diverse and include the production of industrial or
pharmaceutical proteins, and more recently for use as whole-cell
biosensors (Harwood, 1992; Pohl et al., 2013; Webb et al., 2016;
Westers et al., 2004). Cell-free systems could be applied to support
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developments across these applications, particularly, where the func-
tionality of the engineered system relates to aspects of the biochem-
istry, metabolism and/or regulatory processes of B. subtilis as well as
potentially other Gram-positive bacteria. For instance, the cell-free
prototyping of B. subtilis regulatory elements (e.g. promoter libraries)
may provide synergistic beneﬁts when coupled with in vivo studies,
such that multiple rounds of cell-free characterisation workﬂows may
result in more rapid iterations of the design cycle towards the ﬁnal in
vivo design (Chappell et al., 2013; Karim and Jewett, 2016; Tuza et al.,
2013).
However, the initially reported B. subtilis cell-free systems were
typically encumbered by the requirement to use exogenous mRNA,
protease inhibitors, DNAse treatments or less eﬃcient energy systems
(Legault-Demare and Chambliss, 1974; Leventhal and Chambliss,
1979; Nes and Eklund, 1983; Okamoto et al., 1985; Zaghloul and
Doi, 1987) which is perhaps why, despite their potential, these systems
have been largely neglected. In the present study, we report on the
development and improvement of a B. subtilis cell-free system, using a
standardised workﬂow that has no such limitations. We demonstrate
the utility of B. subtilis cell-free transcription-translation systems as a
useful tool for genetic regulatory element prototyping through the
characterisation of an engineered promoter library that enables a range
of comparable in vitro and in vivo transcriptional activities.
Additionally, as a step towards additional applications for B. subtilis
cell-free systems, we characterise an inducible expression system (a
precursor to genetic circuit prototyping) and, characterise the activity
of the Renilla (sea pansy) luciferase (a model enzyme).
2. Materials and methods
2.1. Bacterial strains, plasmids and growth conditions
Bacterial strains used in this study are listed in Table S1. E. coli
strains were grown in Luria-Bertani (LB) medium at 37 °C whilst B.
subtilis strains were grown in 2× YTP medium (31 g/L 2× YT, 40 mM
potassium phosphate dibasic, 22 mM potassium phosphate monoba-
sic) at 30 °C. When applicable, the medium was supplemented with the
following antibiotics: E. coli cultures - ampicillin (Amp) 100 μg/ml;
chloramphenicol (Cam) 50 μg/ml; kanamycin (Kan) 35 μg/ml; B.
subtilis WB800N cultures – chloramphenicol 5 μg/ml; kanamycin
10 μg/ml. Kanamycin is used to select for the neomycin (Neo)
resistance gene in B. subtilis WB800N.
2.2. Strain and plasmid construction
Oligonucleotide primers for plasmid construction and sequencing
are listed in Table S2.
2.2.1. GFPmut3b expression vector
The GFPmut3b expression vector pHT01-gfpmut3b was con-
structed as follows. The insert gfpmut3b was ampliﬁed from plasmid
pAJW26 (BBa_K316008) using primer pair AJW289/AJW290, the
resultant PCR product was puriﬁed, digested with enzymes BamHI and
XbaI and ligated with the vector pHT01, which had been digested with
the same enzymes, resulting in the construction of plasmid pHT01-
gfpmut3b (pAJW107). To remove LacI control, lacI was deleted from
plasmids pHT01 and pHT01-gfpmut3b as follows: inverted PCR
reactions using primer pair AJW320/AJW321 and plasmids pAJW9
and pAJW107 as templates were undertaken, the DNA products were
puriﬁed, phosphorylated, self-ligated and transformed into E. coli
NEB10-beta, resulting in the plasmids pHT01-ΔlacI (pAJW118) and
pHT01-ΔlacI-gfpmut3b (pWK-WT). To generate a pHT01-ΔlacI-
gfpmut3b construct lacking the −35 and −10 boxes and the region
between the two boxes, plasmid pWK-WT was used as the template in
an inverted PCR reaction with primers WK5/WK6. The resultant DNA
product was puriﬁed, phosphorylated, self-ligated and transformed
into E. coli NEB10-beta, resulting in the plasmid pHT01-ΔlacI-Δbox-
gfpmut3b (pWK-Δbox).
2.2.2. Promoter library construction
To construct the promoter library of clones with changes to the −35
and −10 boxes, inverted PCR was undertaken using pWK-WT as the
template and primer pair WK1/WK2. The resultant PCR product was
puriﬁed, phoshporylated, self-ligated, transformed into E. coli NEB10-
beta and the colonies cultured on plates incubated at either 30 °C or
37 °C. This resulted in the production of the pWK(n) plasmid promoter
variants. To create targeted changes to the −10 box, inverted PCR was
undertaken using pWK-WT and pWK5 as the templates and primer
pair WK7/WK8. The products were puriﬁed, phosphorylated, self-
ligated and transformed into E. coli NEB10-beta, resulting in the
plasmids pWK403 and pWK501 respectively. Promoter library clones
tested in this study are listed in Table S6.
2.2.3. GFPmut3b puriﬁcation vector
Primer pair RK003 and RK004 were designed to PCR amplify
gfpmut3b along with the addition of restriction sites BamHI and
HindIII from plasmid pRK1. The subsequent PCR product was
designed so that it could be digested with BamHI and HindIII and
ligated into pre-digested vector pPROEX HTb to form pRK2 – a vector
in which N-terminally His-tagged GFPmut3b protein production could
be induced.
2.2.4. Renilla luciferase vector
Primer pair RK005/RK006 were designed to PCR amplify the
renilla luciferase gene along with the addition of restriction sites
BamHI and XbaI from plasmid pRK5. The subsequent PCR product
was designed so that it could be digested with BamHI and XbaI and
ligated into pre-digested vector pWK-WT to form pRK6 – a vector in
which Renilla Luciferase enzyme could be constitutively expressed.
The DNA of all inserts/constructs were veriﬁed by the sequencing
service provided by Euroﬁns Genomics GmbH (Ebersberg, Germany).
Primers AJW10 and AJW11 were used to sequence pSB1C3 based
constructs and primers AJW77, AJW78, AJW322 and AJW376 were
used to sequence either pHT01 or pHT01-ΔlacI based constructs.
Primer WK3 was used to sequence the gfpmut3b constructs whilst
primers RK001 and RK002 were used to sequence pPROEX HTb His-
gfpmut3b.
2.3. Cell-free extract preparation
To prepare cell-free extracts, B. subtilis 168 cells were revived from
glycerol stocks onto LB plates whilst B. subtilis WB800N cells were
revived from glycerol stocks onto LB plates supplemented with
kanamycin (Kan;10 µg/ml). Once streaked, plates were incubated for
48 h at 30 °C. Individual colonies were inoculated into 5 ml 2× YTP
medium and incubated for 10 h with shaking (180 rpm) at 30 °C. The
resultant cultures were diluted (1:500) into ﬂasks containing 50 ml 2×
YTP medium and incubated for 10 h with shaking (180 rpm) at 30 °C.
Resultant cultures were either harvested for cell lysis or, for larger
scales of production, they were diluted (1:500) into ﬂasks containing
500 ml 2× YTP medium and incubated for 10 h with shaking (180 rpm)
at 30 °C. To harvest cells, 500 ml cultures were centrifuged at 3,220g
for 15 min. Cell pellets were re-suspended into 20 ml S30-A buﬀer
(14 mM Magnesium (Mg) glutamate, 60 mM Potassium (K) glutamate,
50 mM Tris, 2 mM DTT, pH 7.7) and transferred into a pre-weighed
50 ml Falcon tube. Each 50 ml Falcon tube was centrifuged (2,000g,
10 min, 4 °C), pellets washed with 20 ml S30-A buﬀer and subse-
quently re-centrifuged (2,000g, 10 min, 4 °C) to form the ﬁnal cell
pellets in preparation for cell lysis. To determine the weight of the cell
pellet, the weight of the 50 ml falcon tube was subtracted from the
combined weight of the 50 ml tube and cell pellet. Pellets were stored at
−80 °C for no more than 48 h, prior to cell lysis.
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To lyse the cells, pellets were defrosted on ice and re-suspended
into 1 ml S30-A buﬀer per gram of cell pellet and aliquoted as 1 ml
samples in 1.5 ml microtubes. Samples were sonicated on ice (3×40 s
with 1-min cooling interval; output frequency: 20 kHz; amplitude:
50%) and then centrifuged (12,000g at 4 °C for 10 min). The super-
natants were removed, aliquoted at 500 μl into 2 ml screw cap tubes
and incubated with shaking (180 rpm) at 37 °C for either 0, 30 or
80 min. Post pre-incubation, samples were stored on ice and then
centrifuged (12,000g at 4 °C for 10 min). Supernatants were removed
and were either aliquoted into 1.5 ml tubes that were stored on ice or
into dialysis cassettes (GeBAﬂex-Maxi Dialysis Tubes −8 kDa MWCO,
Generon) for dialysis into S30-B buﬀer (14 mM Mg-glutamate, 60 mM
K-glutamate, ~5 mM Tris, 1 mM DTT; pH 8.2) with stirring at 4 °C for
3 h. Post-dialysis samples were centrifuged (12,000g at 4 °C for
10 min), the extract supernatants from all conditions were aliquoted
into 1.5 ml tubes, ﬂash frozen in liquid nitrogen and stored at −80 °C
for use in cell-free reactions. The protein concentration of cell extracts
was measured using a Bradford Assay (Biorad, CA, USA).
2.4. Cell-free transcription-translation reactions
Cell-free reactions were 10 μl in total and consisted of three parts
mixed together in the indicated ratios: cell extract (33% or 50% v/v),
energy buﬀer (42% v/v) and DNA (25% or 8% v/v). The ﬁnal reaction
conditions were: 4–12 mM Mg-glutamate, 40–160 mM K-glutamate,
1.5 mM each amino acid (except leucine −1.25 mM leucine) [RTS
Amino Acid Sampler, 5-Prime, DE], 50 mM HEPES, 1.5 mM ATP and
GTP, 0.9 mM CTP and UTP, 0–0.2 mg/ml E. coli tRNA, 0.26 mM CoA,
0.33 mM NAD, 0.75 mM cAMP, 0.068 mM folinic acid, 1 mM spermi-
dine, 2% (w/v) PEG-8000, 30 mM 3-PGA and 0–12 nM plasmid DNA.
10 μl cell-free reactions were aliquoted into individual wells of 384-well
plates (Griener bio-one, NC, USA) and measured using a Clariostar
plate reader (BMG, UK) with the following settings: excitation 483 nm
and emission 530–30 nm. Plates were sealed, shaken prior to each
reading cycle (500 rpm) and the plate reader was set to incubate the
cell-free reactions at 30 °C.
2.5. In vitro cell-free transcription-translation promoter library
characterisation
Cell-free transcription-translation reactions were 10 μl in total and
consisted of three parts mixed together in the indicated ratios: cell
extract (33% v/v), optimised energy buﬀer (42% v/v) and DNA (25% v/
v). The ﬁnal reaction conditions were: 8 mM Mg-glutamate,
160 mM K-glutamate, 1.5 mM each amino acid (except leucine
−1.25 mM leucine), 50 mM HEPES, 1.5 mM ATP and GTP, 0.9 mM
CTP and UTP, 0.2 mg/ml E. coli tRNA, 0.26 mM CoA, 0.33 mM NAD,
0.75 mM cAMP, 0.068 mM folinic acid, 1 mM spermidine, 2% PEG-
8000, 30 mM 3-PGA and 10 nM plasmid DNA. 10 μl cell-free reactions
were aliquoted into individual wells of 384-well plates (Griener bio-
one), measured using a Clariostar plate reader (BMG) with the
following settings; Excitation 483 nm and Emission 530–30 nm.
Plates were sealed, shaken prior to each reading cycle (500 rpm) and
the plate reader was set to incubate the cell-free reactions at 30 °C. The
relative strength of the promoters was calculated from the rate of
ﬂuorescence increase during a phase of increasing GFPmut3b expres-
sion (20–80 min). The background ﬂuorescence of cell-free reactions
using the control plasmid (pHT01-ΔlacI), were subtracted and these
data were normalised to the relative strength of prWK-WT which was
denoted a relative strength of 1.
2.6. In vivo promoter library characterisation
Promoter library constructs selected for in vivo characterisation,
along with the pHT01-ΔlacI empty vector control, were transformed
into B. subtilis WB800N using the two-step transformation procedure
as described previously (Cutting and Vander Horn, 1990) and trans-
formants were selected on LB agar containing the appropriate anti-
biotics. This resulted in strains WB800N pHT01-ΔlacI (AJW25),
WB800N pWK-WT (WK1), WB800N pWK-Δbox (WK2), WB800N
pWK1 (WK3), WB800N pWK28 (WK4), WB800N pWK76 (WK5),
WB800N pWK104 (WK6), WB800N pWK105 (WK7), WB800N
pWK118 (WK8), WB800N pWK120 (WK9), WB800N pWK301
(WK10), WB800N pWK319 (WK11), WB800N pWK603 (WK12) and
WB800N pWK609 (WK13).
2.6.1. Plate reader characterisation
Promoter library strains were revived from glycerol stocks onto LB
plates supplemented with the appropriate antibiotics and incubated for
48 h at 30 °C. Individual colonies were inoculated into 5 ml 2x YTP
medium with appropriate antibiotics and incubated overnight with
shaking (180 rpm) at 30 °C. The overnight cultures were diluted to an
OD600 nm of 0.05 in fresh 2x YTP with appropriate antibiotics and
100 μl aliquots loaded onto a 96-well black plate with clear ﬂat bottoms
(Greiner Bio-one, At; Cat #655076). Absorbance (600 nm) and ﬂuor-
escence (Excitation 483 nm, Emission 530–30 nm) was measured
every ten minutes at 30 °C, with shaking at 700 rpm between each
measurement in a BMG Clariostar plate reader (BMG, UK). Each strain
was analysed using 3 independent cultures, with each culture being
tested in triplicate. The relative strength of the promoters was
calculated as the rate of ﬂuorescence (GFPmut3b) per cell growth
(OD600 nm) increase during a set time period (240–300 min). The
background ﬂuorescence of 2x YTP cell growth media and cells
transformed with the negative control plasmid (pHT01-ΔlacI) were
subtracted and these data were normalised to the relative strength of
pWK-WT which was denoted an RPU of 1.
2.6.2. Flow cytometry characterisation
Promoter library strains were revived from glycerol stocks onto LB
plates supplemented with the appropriate antibiotics and incubated for
48 h at 30 °C. Three individual colonies were selected for each strain,
separately inoculated into 5 ml 2x YTP medium with appropriate
antibiotics and incubated overnight with shaking (180 rpm) at 30 °C.
Overnight cultures were diluted to an OD600 nm of 1.0. 1 ml of diluted
cell cultures were centrifuged (12,470g) and washed twice with 1 ml
Phosphate Buﬀered Saline (1X PBS). Finally, cell pellets were re-
suspended into 1 ml PBS, then diluted (1:1000) into PBS before being
loaded onto an Attune NxT (ThermoFisher Scientiﬁc, MA, USA) ﬂow
cytometer. The ﬂuorescence (Geometric mean BL1-A; Ex. 488 nm, Em.
530/30) of at least 30,000 cells per sample were measured and these
data were analysed using FlowJo (vX 10.1r5) software. The background
ﬂuorescence (BL1-A) of cells transformed with the negative control
plasmid (pHT01-ΔlacI) were subtracted and these data were normal-
ised to the relative strength of pWK-WT which was denoted a relative
strength of 1.
2.7. GFPmut3b expression and puriﬁcation
A culture of glycerol stocked E. coli containing plasmid pROEX
HTb His-gfpmut3b (pRK2) was used to inoculate 5 ml LB supplemen-
ted with 100 µg/ml ampicillin. The culture was grown with shaking
(180 rpm) for 16 h at 37 °C. Subsequently, the culture was diluted
(1:500) into 500 ml LB supplemented with 100 µg/ml ampicillin, and
1 mM IPTG and grown with shaking (180 rpm) for 24 h at 37 °C. The
cell pellet was harvested through centrifugation at 3,220g for 15 min
and stored at −80 °C. Pellets were defrosted on ice and re-suspended
into 1 ml re-suspension buﬀer (50 mM Na2HPO4, 100 mM NaCl
titrated to pH 8 with HCl/NaOH) per gram of cells. Re-suspended
cells were sonicated (3×40 s with 1-min cooling interval; output
frequency: 20 kHz, Amplitude: 50%) and centrifuged (2000g, 10 min,
4 °C) to produce a clariﬁed extract. His–GFPmut3b was puriﬁed from
the clariﬁed extract using a Ni-NTA column with wash buﬀer (50 mM
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Na2HPO4, 100 mM NaCl, 25 mM Imidazole, titrated to pH 8 with HCl/
NaOH) and elution buﬀer (50 mM Na2HPO4, 100 mM NaCl, 500 mM
Imidazole, titrated to pH 8 with HCl/NaOH). The eluted His–
GFPmut3b puriﬁed fraction was dialysed using dialysis tubing
(MWCO 12–14,000 kDa) suspended in 1 L dialysis buﬀer (20 mM
HEPES, 100 mM NaCl, dH2O pH 8 with KOH) overnight with stirring,
in the dark, at 4 °C. The protein concentration of the puriﬁed His–
GFPmut3b was determined using a Nanodrop ND-1000 spectrophot-
ometer (Thermo Scientiﬁc). GFP puriﬁcation samples were analysed
via sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis
(PAGE) using 4–12% Bis-Tris gels (NuPAGE Novex, Lifetech), followed
by either coomassie blue staining or western blot analysis with HRP-
conjugated GFP-speciﬁc polyclonal antibody (1:4,000 dilution;
#A10260, Thermo Fisher Scientiﬁc Ltd, UK). Western blots were
developed by enhanced chemiluminence (ECL).
2.8. GFPmut3b calibration curve
GFPmut3b calibration curve reactions (10 μl) were setup similarly
to typical cell-free reactions, but without DNA, and consisted of three
parts mixed together in the indicated ratios: cell extract (33% v/v),
buﬀer (42% v/v) and puriﬁed His-GFPmut3b (25% v/v). The
GFPmut3b calibration solutions contained: 8 mM Mg-glutamate,
160 mM K-glutamate, 1.5 mM each amino acid (except leucine
−1.25 mM leucine), 50 mM HEPES, 1.5 mM ATP and GTP, 0.9 mM
CTP and UTP, 0–0.2 mg/ml E. coli tRNA, 0.26 mM CoA, 0.33 mM
NAD, 0.75 mM cAMP, 0.068 mM folinic acid, 1 mM spermidine, 2%
PEG-8000, 30 mM 3-PGA and 0–1.09 µM His–GFPmut3b. The cali-
bration curve reactions were aliquoted into 384-well plates (Greiner
Bio-One, At) and measured using a Clariostar plate reader (BMG, UK)
with the following settings: Excitation 483 nm, Emission 530–30 nm.
2.9. Luciferase assay
Cell-free transcription-translation reactions were 10 μl in total and
consisted of three parts mixed together in the indicated ratios: cell
extract (33% v/v), optimised energy buﬀer (42% v/v) and DNA (25% v/
v). Cell-free reactions were setup to include either 10 nM (ﬁnal
concentration) of pHT01-ΔlacI or pHT01-ΔlacI-Renilla plasmid con-
structs. Cell-free reactions were incubated for 3 h at 30 °C. Post-
incubation, cell-free reactions were transferred into white assay plates
(Greiner Bio-One 96-well half-area) and assayed, according to manu-
facturer's guidelines, for detection of luciferase activity using a
commercially available Renilla luciferase assay kit (Promega, WI,
USA; Cat# E2810). Bioluminescence was measured using a Clariostar
plate reader (BMG, UK) with the following settings: bioluminescence
emission was measured at 480–80 nm and the plate reader was set to
incubate the cell-free reactions at 30 °C.
3. Results and discussion
3.1. Cell-free workﬂow
The primary focus of this study was to develop a robust B. subtilis
cell-free transcription-translation system that could be applied towards
applications that are of interest to synthetic biologists and metabolic
engineers such as cell-free protein synthesis, or regulatory element
prototyping. To this end, our initial aim was to implement a standar-
dised workﬂow of extract preparation and reaction optimisations that
could be tailored towards the minimisation of cell extract batch
variation and improvement of cell-free protein production yields. The
workﬂow was developed for B. subtilis, though it incorporates aspects
of several diﬀerent established cell-free transcription-translation pro-
tocols (Shin and Noireaux, 2012; Shrestha et al., 2012; Sun et al.,
2013) and consists of three phases – harvest cells, extract preparation
and cell-free reaction optimisation (Fig. 1)..
During the cell growth phase B. subtilis strains were revived from
glycerol stocks onto LB plates and incubated for 48 h at 30 °C. From
these, individually selected colonies were used to inoculate 5 ml
cultures (2× YTP media) that were grown for 10 h with shaking at
30 °C. These cultures were then diluted (1:500) into 50 ml 2× YTP
media and grown for 10 h with shaking at 30 °C, after which the cells
were harvested during a late log phase of cell growth (Fig. S1a).
Alternatively, if larger batches were required then cultures could be
diluted once more (1:500) into 500 ml 2× YTP media and grown for a
ﬁnal 10 h with shaking at 30 °C. For practical purposes, cells were
harvested at the 50 ml growth stage since this produced enough cell
extract for downstream characterisation experiments. These growth
conditions were suﬃcient such that the ﬁnal harvest OD600 nm of both
B. subtilis strains −168 (3.133 ± 0.033) and WB800N (2.722 ± 0.072)
were consistent between batches of the same strain (Fig. S1b). Cell
pellets were harvested through centrifugation, washed and stored at
−80 °C until the extract preparation phase.
During the extract preparation phase cell pellets were defrosted
slowly on ice, re-suspended in 1 ml S30-A buﬀer per gram of cell pellet
and each millilitre of cell and buﬀer mixture aliquoted into separate
1.5 ml microtubes. These samples were sonicated and then centrifuged
to produce a clariﬁed cellular extract. In order to produce cellular
extracts that have optimal cell-free transcription-translation activity,
clariﬁed cellular extracts were aliquoted into distinct downstream
processing groups. Cellular extracts were pre-incubated at 37 °C with
shaking (180 rpm) for either 0, 30 or 80 min. Similarly, to reports of E.
Fig. 1. Cell-free workﬂow. A graphical depiction of the workﬂow used to develop and
characterise B. subtilis cell-free systems.
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coli cell-free extract preparation methods, the pre-incubation tempera-
ture inﬂuences the performance of cellular extracts in downstream cell-
free transcription-translation reactions (Sushmita et al., 2015). We
observed that B. subtilis WB800N extracts prepared with a pre-
incubation temperature of 30 °C displayed a reduction in cell-free
transcription-translation activity in comparison to cell extracts pre-
pared with a pre-incubation temperature of 37 °C (Fig. S2). Therefore,
we typically pre-incubated cell extracts at 37 °C.
Upon completion of the pre-incubation step the cell extracts were
processed either with or without dialysis treatment at 4 °C, with
stirring, for 3 h. This resulted in the generation of six diﬀerently
processed cellular extracts from each cell batch. The total protein
content of these cellular extracts was analysed using Bradford assays.
The total protein concentrations of B. subtilis 168 cellular extracts
varied between cell batches and between the diﬀerent extract proces-
sing methods, particularly for those extracts that were pre-incubated
(Fig. S1c). In contrast, the total protein concentrations of B. subtilis
WB800N cellular extracts were largely consistent across batches and
processing methods (Fig. S1c). Processed cellular extracts were ﬂash
frozen in liquid nitrogen and stored at −80 °C until used.
Processed extracts were assessed in terms of their cell-free tran-
scription-translation reaction activities using a previously described
(Sun et al., 2013) standard energy buﬀer (Table S3), and 10 nM of
plasmid DNA. In this study, we chose to use the B. subtilis plasmid
pHT01 as the backbone for our constructs in cell-free reactions since it
has been previously validated as a stable expression vector for the
production of recombinant proteins (Nguyen et al., 2007). The
ﬂuorescent reporter GFPmut3b was cloned into this plasmid to create
the construct pHT01-gfpmut3b, such that the expression of gfpmut3b
would be under the control of the lacI repressible Pgrac (σA)
promoter. Addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG)
for inhibition of LacI repression enables the inducible expression of
GFPmut3b (Fig. 2a; Fig. 5b). However, when pHT01-gfpmut3b was
tested in B. subtilis cell-free reactions, GFPmut3b production occurred
regardless of IPTG induction (Fig. S3a). As such, the pHT01-gfpmut3b
plasmid eﬀectively resulted in the constitutive expression of gfpmut3b.
Since the LacI repressor proteins are not present in the B. subtilis
WB800N cell extract and are instead constitutively expressed from the
lacI gene that is encoded into pHT01, it is likely that there are
insuﬃcient LacI repressor proteins during the early stages of the cell-
free reaction. The unnecessary repressor lacI gene was removed, using
PCR, from plasmids pHT01 and pHT01-gfpmut3b to create a negative
control plasmid (pHT01-ΔlacI) and a constitutive gfpmut3b expression
plasmid (pWK-WT) (Fig. 2a; Fig. S3b; Fig. S4) that were subsequently
used to test and compare cell-free reaction activities..
During the ﬁnal phase of the workﬂow the most productive cellular
Fig. 2. Characterisation of a Bacillus subtilis 168 cell-free transcription-translation system: (a) Schematic of the constructs used to characterise B. subtilis cell free systems. Circuits
were visualised using Pigeon (Bhatia and Densmore, 2013). (b) Endpoints (5 h) of cell-free reactions using cell-extract batches prepared as indicated - including 0, 30 or 80 min pre-
incubation at 37 °C, followed either with or without dialysis treatment. The background ﬂuorescence of cell-free reactions using the negative control plasmid (pHT01-ΔlacI), were
subtracted. (c) Example time-course cell-free reactions using cell extracts that were prepared as indicated - including 0, 30 or 80 min pre-incubation at 37 °C, followed either with or
without dialysis treatment. Cell-free reactions contained either the negative control plasmid – pHT01-ΔlacI (indicated black) or pWK-WT (indicated green). Error bars denote standard
error of the mean.
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extracts were improved through additional cell-free reaction optimisa-
tion steps. Emphasis was placed on changing the concentrations of
magnesium glutamate and potassium glutamate in the energy buﬀer
since these have previously been shown to have a signiﬁcant inﬂuence
on cell-free reaction activity (Cai et al., 2015; Sun et al., 2013). Upon
completion of the workﬂow the extract preparation method and energy
buﬀer composition that resulted in the greatest yield of GFPmut3b
production could then be used for all subsequent batches. We initially
used the workﬂow to characterise a B. subtilis 168 cell-free system.
3.2. Characterisation of a Bacillus subtilis 168 cell-free system
B. subtilis 168 is an established and highly characterised strain
whose genomic heritage spans several decades to the extent that its
origins can be traced back to some of the earliest isolated legacy strains
(Burkholder and Giles, 1947; Zeigler et al., 2008). B. subtilis 168 is a
domesticated strain and as such, it is relatively easy to culture and
genetically engineer (Guan et al., 2016; Zeigler et al., 2008). These
characteristics have made B. subtilis 168 a suitable choice for a broad
array of industrial biotechnology applications and more recently as a
suitable host for synthetic biology (Harwood et al., 2013). The
universal utility of B. subtilis 168 suggests that the development of a
B. subtilis 168 cell-free transcription-translation system would be a
useful platform for synthetic biology and metabolic engineering
applications.
In order to develop a B. subtilis 168 cell-free system, three
independently generated batches of B. subtilis 168 were cultured,
harvested and the resultant cell extracts processed using the cell-free
workﬂow described in Fig. 1. These extracts were combined with the
standard energy buﬀer and 10 nM (ﬁnal concentration) of either the
negative control plasmid (pHT01-ΔlacI) or the constitutive GFPmut3b
expression plasmid (pWK-WT) to form cell-free reactions for testing.
Replicate reactions were aliquoted into a 384 well plate and measured
in parallel. Cell-free production of GFPmut3b was measured every ten
minutes for ﬁve hours at 30 °C using a Clariostar plate reader, with
shaking before each measurement cycle to support oxygenation and
mixing of the cell-free reactions. However, cell-free reactions using B.
subtilis 168 cell extracts showed relatively little transcription and/or
translation activity (Fig. 2b; Fig. 2c). Indeed, end-point (5 h) analysis of
GFPmut3b production across all cell-extract batches that were pre-
pared as indicated - including 0, 30 or 80 min pre-incubation (37 °C),
followed either with, or without dialysis treatment, produced low and
unreliable yields of GFPmut3b (Fig. 2b). GFPmut3b yields, calculated
using a GFPmut3b calibration curve (Fig. S5c), ranged from eﬀectively
0–0.011 µM ± 0.003 (pre-incubation for 0 min, without dialysis). A
complete analysis of these data is shown in Table S4. Whilst alternative
extract processing methods or energy buﬀers may improve cell-free
activity, it is possible that despite the advantages of B. subtilis 168 in
vivo, the strain is not intrinsically suitable for use in cell-free
transcription-translation reactions. This could be due to the presence
of endogenously expressed proteases and a resultant degradation of
translated proteins. Indeed, previously reported B. subtilis cell-free
systems were typically encumbered by a requirement to include
protease inhibitors (Table 1). Rather than to optimise B. subtilis 168
cell-free activity through the addition of a cocktail of protease
inhibitors, we decided to circumvent these limitations through the
development of a B. subtilis cell-free system that uses cellular extracts
from a protease deﬁcient strain - B. subtilis WB800N (Nguyen et al.,
2011).
3.3. The development of a B. subtilis WB800N cell-free system
B. subtilis WB800N (MoBiTech, GmbH) is a commercially acces-
sible strain that has been developed for the production and secretion of
heterologous proteins (Nguyen et al., 2011). B. subtilis WB800N was
engineered to be neomycin resistant and deﬁcient for the expression of Ta
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several proteases (nprE aprE epr bpr mpr::ble nprB::bsr Δvpr
wprA::hyg cm::neo; NeoR) (Fig. 3a). Similarly, to the generation of
B. subtilis 168 extracts, three independently generated batches of B.
subtilis WB800N cells were cultured, harvested and the resultant
extracts were processed using the cell-free workﬂow described in
Fig. 1. Cell-free reactions using B. subtilis WB800N cell-extracts were
most active during the ﬁrst 0–150 min and were generally more active,
in terms of GFPmut3b production, than B. subtilis 168 cell-extracts
Fig. 3. Development of a Bacillus subtilisWB800N cell-free transcription-translation system. (a) B. subtilisWB800N is an engineered strain in which the indicated proteases (X) have
been knocked-out. Adapted from (Westers et al., 2004). (b) Endpoints (5 h) of cell-free reactions using cell extract batches prepared as indicated - including 0, 30 or 80 min pre-
incubation at 37 °C, followed either with or without dialysis treatment. The background ﬂuorescence of cell-free reactions using the negative control plasmid (pHT01-ΔlacI), were
subtracted. (c) Representative time-courses of cell-free reactions using cell-extracts that were prepared as indicated - including 0, 30 or 80 min pre-incubation at 37 °C, followed either
with or without dialysis treatment. Cell-free reactions contained either the negative control plasmid – pHT01-ΔlacI (indicated black) or pWK-WT (indicated green). (d) Optimisation of
cell-free buﬀer components: magnesium glutamate and potassium glutamate. These data are representative of endpoint (5 h) analysis of cell-free reactions from three independently
prepared extracts. The background ﬂuorescence of cell-free reactions using the negative control plasmid (pHT01-ΔlacI), were subtracted. (e) Endpoints (5 h) of optimised cell-free
reactions that include a range of diﬀerent plasmid DNA (pWK-WT) concentrations. The background ﬂuorescence of cell-free reactions using the negative control plasmid (pHT01-ΔlacI),
were subtracted. Error bars denote standard error of the mean.
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(Fig. 3b; Fig. 3c). Based upon an analysis of end-point (5 h) GFPmut3b
cell-free reaction yields, WB800N cell-extracts (Fig. 3b) produced
higher and more consistent yields of GFPmut3b than B. subtilis 168
cell-extracts (Fig. 2b). WB800N cell-free GFPmut3b production yields,
calculated using a GFPmut3b calibration curve (Fig. S5c), ranged from
0.041 µM ± 0.008 (pre-incubation for 80 min, without dialysis) to
0.116 µM ± 0.009 (pre-incubation at 37 °C for 80 min, followed by
dialysis) (Table S4)..
In continuation of the cell-free workﬂow (Fig. 1) additional experi-
ments were undertaken to further improve B. subtilis WB800N cell-
free transcription-translation reactions through changes in the compo-
sition of the energy buﬀer. The concentrations of magnesium glutamate
(Mg-glutamate) and potassium glutamate (K-glutamate) in the stan-
dard energy buﬀer were altered since these have been previously shown
to have a signiﬁcant inﬂuence on cell-free reaction activity. Previous
reports have demonstrated that glutamate is utilised in the TCA cycle of
cellular extracts and is therefore able to serve as an energy substrate
that supports ATP generation and protein production (Jewett et al.,
2008). The processing conditions that included 80 min pre-incubation
at 37 °C and dialysis produced the most active cellular extracts and
therefore, these conditions were used for the generation of three
additional B. subtilis WB800N extract batches. These processed cell
extracts were combined with 10 nM (ﬁnal concentration) of either
pHT01-ΔlacI (control) or pWK-WT plasmid DNA and energy buﬀers
that were similar in composition to the standard energy buﬀer, except
that they contained diﬀerent combinations of K-glutamate
(40−160 mM) and Mg-glutamate (4 mM−12 mM) concentrations. In
comparison to the standard energy buﬀer, which enabled the cell-free
production of 0.281 µM ± 0.019 GFPmut3b, an optimised energy
buﬀer that included 160 mM K-glutamate and 8 mM Mg-glutamate
resulted in an improved GFPmut3b production yield of 0.500 µM ±
0.052 (Fig. 3d; Table S3; Table S5).
An additional batch of B. subtilis WB800N cell extract was
processed using our improved protocol. This new batch of cell extract
was used to setup several cell-free reactions that when tested with a
range of diﬀerent pWK-WT plasmid DNA concentrations produced up
to 0.848 µM ± 0.047 of GFPmut3b (Fig. 3e). In these experiments,
there was generally a linear relationship between DNA concentration
(pWK-WT) and cell-free GFPmut3b production however, when the
ﬁnal DNA concentration was increased above 8 nM this linearity did
not continue. Essentially, further increases in DNA concentration
above 8 nM did not result in signiﬁcant increases in GFPmut3b
production. It is possible that relatively high concentrations of plasmid
DNA pose a maximal usage of available transcription (e.g. RNA
polymerases) and/or translation (e.g. ribosomes) machinery in the cell
extract that is limiting any further improvements in cell-free reaction
performance (Ceroni et al., 2015). As a preliminary test, we explored
whether an increase in the proportion of cellular extract from 33% (v/
v) to 50% (v/v) of the total cell-free reaction volume would improve
cell-free transcription-translation activity. As expected, increasing the
volume of cellular extract (to 50% v/v) and as a likely consequence,
increasing the availability of transcription and/or translation machin-
ery, resulted in a greater level of cell-free reaction activity (Fig. S6). In
separate experiments, we observed that the addition of E. coli tRNAs
improved the activity of B. subtilis WB800N cell-free transcription-
translation reactions but were not essential (Fig. S7). Thus, whilst we
cannot discount the possibility that further improvements in B. subtilis
WB800N cell-free activity might be hampered by the availability of core
cellular machinery (e.g. active ribosomes) in the cell-free extract, these
data suggest that at least some of the translational resources (e.g.
tRNAs) may not be a signiﬁcant limiting factor.
Future studies may also need to consider additional factors that
might be impacting B. subtilis WB800N cell-free reaction activity. For
instance, there are reports that changes in pH as a result of the build-
up of glycolytic lactate and acetate production, as well as the produc-
tion of inorganic phosphates during cell-free reactions can also be
deleterious to cell-free activity (Caschera and Noireaux, 2015b, 2014).
These limiting factors may be mitigated through changes in the energy
source that is used. For example, Maltose is a novel energy source that
enables the recycling of inhibitory inorganic phosphates in E. coli cell-
free systems (Caschera and Noireaux, 2014). Therefore, in future
studies, it may be possible to further improve B. subtilis cell-free
activity through an investigation of these potentially inhibitory factors
and to assess whether changes in the energy buﬀer composition might
mitigate any limiting eﬀects.
3.4. Generation of an engineered promoter library
In order to improve the ability of synthetic biologists and metabolic
engineers to precisely ﬁne tune gene expression there is an increasing
interest towards expanding the availability of characterised genetic
regulatory elements (e.g. promoters) (Guiziou et al., 2016; Moore et al.,
2016; Patron et al., 2015). As demonstration of the applicability of B.
subtilis cell-free transcription-translation systems for regulatory ele-
ment prototyping we applied our improved B. subtilis WB800N cell-
free system towards the characterisation of an engineered B. subtilis
promoter library that enables a range of transcriptional activities in
vitro (cell-free) and in vivo. The engineered promoter library was
created using degenerate oligonucleotides that were designed to bind to
the −35 and −10 boxes of the Pgrac (σA) promoter in plasmid pWK-
WT, and introduce, through an inverted PCR, changes into the
promoter sequence (Fig. 4a). This strategy should result in enough
random changes to both boxes (−10 and −35) to give a theoretical
library size of up to 412 (1,6777,216) diﬀerent engineered promoters.
Several library clones were screened via sequencing and those with
sequence changes that diﬀered from the reference wildtype Pgrac
promoter, which we renamed as prWK-WT, were retained for further
studies. The promoter library sequences obtained are shown in Fig. S8.
The plasmid - pWK-Δbox was also engineered as an additional negative
control in which primers were designed to remove, via PCR from
plasmid pWK-WT, both the −35 and −10 boxes of the Pgrac (σA)
promoter, as well as the sequence between them. Thus, plasmid pWK-
Δbox did not promote gfpmut3b expression (Fig. 4b; Fig. S9; Fig. S10b;
Fig. S11; Table S7; Table S8)..
An initial screen of cell-free GFPmut3b production from 58
diﬀerent engineered promoter constructs was carried out using the
improved B. subtilis WB800N cell-free system. Our initial screening
identiﬁed several promoters that displayed a range of diﬀerent
transcriptional strengths. Engineered promoters that resulted in the
highest levels of gfpmut3b expression were selected for further analysis
(Fig. S9). Of these, clones: pWK1, pWK28, pWK76, pWK104, pWK105,
pWK118, pWK120, pWK301, pWK319, pWK603, and pWK609, were
characterised for both in vitro (cell-free transcription-translation) and
in vivo gfpmut3b expression.
Similarly to previous reports (Chappell et al., 2013; Kelly et al.,
2009) we assessed the relative strength of these engineered promoters
using cell-free transcription-translation (in vitro), plate reader (in
vivo) and ﬂow cytometry (in vivo) assays (Fig. 4b). These assays are
described in more detail in the materials and methods section. Brieﬂy,
for cell-free transcription-translation characterisation of the promoter
library the relative strength of the promoters was calculated from the
rate of ﬂuorescence increase during a phase of increasing GFPmut3b
expression (20–80 min) and then these rate change data were normal-
ised (including removal of the background signal) to the relative
strength of prWK-WT. Whilst, for in vivo analysis, promoter library
strains (B. subtilis WB800N) were cultured in 96-well plates and
assayed using a Clariostar plate reader (Fig. S10). The relative strength
of the promoters was calculated as the rate of ﬂuorescence (GFPmut3b)
increase per cell growth (OD600 nm) during a set time period (240–
300 min). and then these rate change data were normalised (including
removal of the background signal) to the relative strength of prWK-WT.
Finally, as an additional assessment, the promoter library strains (B.
R. Kelwick et al. Metabolic Engineering xx (xxxx) xxxx–xxxx
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subtilis WB800N) were cultured overnight, washed in PBS and loaded
into an Attune NxT ﬂow cytometer for analysis of GFPmut3b ﬂuores-
cence (Geometric mean BL1-A) (Table S8.). These data were subse-
quently normalised (including removal of the background signal) to the
relative strength of prWK-WT.
We observed signiﬁcant diﬀerences in activity between promoters
that were largely similar in sequence. For example, the sequences of
prWK104 and prWK1 diﬀer by only two base changes (−35 box: T > C;
−10 box: G > A) yet, on relative terms, prWK104 is roughly four times
stronger than prWK1. It is likely, that these base changes are
inﬂuencing the biophysical interaction (e.g. binding aﬃnity) between
the promoter region on the plasmid DNA and the transcriptional
machinery (e.g. RNA polymerase and sigma factor) (Guiziou et al.,
2016). Interestingly, the general pattern of relative promoter strengths
in the engineered library were similar both in vitro (cell-free) and in
vivo (Fig. 4b; Table S7). Comparability between the relative activity of
genetic regulatory elements tested in cell-free transcription-translation
reactions and in vivo has been previously demonstrated in E. coli
(Chappell et al., 2013; Sun et al., 2014). Comparability between cell-
free and in vivo characterised DNA regulatory elements is important
within a systematic design context – through which, it is envisioned
that cell-free workﬂows may rapidly provide the characterisation data
required to rationally select a smaller number of designs for ﬁnal
testing in vivo. Therefore, whilst further investigations are needed to
assess the in vivo comparability of in vitro characterised B. subtilis
genetic regulatory elements, characterisation of our engineered pro-
moter library suggests that B. subtilis cell-free systems are a viable
platform for regulatory element prototyping.
3.5. Characterisation of a B. subtilis WB800N-pHT01 cell extract for
inducible gene expression
Genetic circuit engineering lies at the foundations of synthetic
biology (Collins et al., 2000; Elowitz and Leibler, 2000) and there is a
growing interest in utilising cell-free transcription-translation systems
to iterate increasingly more complex genetic circuit designs
(Niederholtmeyer et al., 2015; Noireaux et al., 2003; Zhang et al.,
2016). Therefore, it is likely that as the availability of characterised B.
subtilis regulatory elements increases there will be an increase in the
potential for using B. subtilis cell-free transcription-translation systems
to support the development of B. subtilis-based genetic circuits (Jeong
et al., 2015). Consequently, as an initial step towards the emergence of
genetic circuit prototyping in B. subtilis cell-free systems we charac-
terised an inducible expression system. The protease deﬁcient strain -
B. subtilis WB800N was previously transformed with plasmid pHT01
to create the engineered strain - WB800N-pHT01 (AJW5) which
constitutively expresses the lacI gene (Fig. 5a) (Webb et al., 2016).
Three independent batches of B. subtilis WB800N-pHT01 cell extracts
were generated using the same method that improved the cell-free
activity of B. subtilisWB800N cell extracts (pre-incubation at 37 °C for
80 min, followed by dialysis). As expected, the presence of LacI
repressor protein within B. subtilis WB800N-pHT01 cell extracts was
suﬃcient to inhibit (turn “OFF”) GFPmut3b expression from pHT01-
based plasmids in cell-free transcription-translation reactions (Fig. 5b;
Fig. 5c; Fig. S12). Likewise, addition of 0.0625–1 mM IPTG for
inhibition of LacI repression resulted in a robust induction (turn
“ON”) of GFPmut3b expression from pHT01-gfpmut3b plasmid –
producing a ﬂuorescent signal that was 117–147 fold above back-
ground (Fig. 5b; Fig. 5c). Whilst, there was a modest induction increase
between the lowest (0.0625 mM) and highest (0.5–1 mM) concentra-
tions of IPTG that were tested, it may be possible to achieve a larger
dynamic range of induction levels if a broader range of IPTG
concentrations are used. Nevertheless, these inducible expression data
suggest that it may be possible, in future studies, to use these B. subtilis
cell-free systems to characterise simple genetic circuits..
3.6. Characterisation of Renilla luciferase activity in B. subtilis
WB800N cell-free reactions
The luciferase gene from Renilla reniformis (sea pansy) encodes a
decarboxylating enzyme that is capable of catalyzing the oxidation of
Coelenterazine to Coelenteramide. As a consequence, cabon dioxide
(CO2) and bioluminescence (480 nm) are produced (Lorenz et al.,
1991; Matthews et al., 1977). The bioluminescence capabilities of
Renilla luciferase have been extensively characterised and repurposed
for use in an array of contexts and biological assays (Hampf and
Gossen, 2006). We carried out cell-free protein expression and
characterisation of Renilla luciferase activity in B. subtilis WB800N
cell-free extracts. Cell-free reactions including either 10 nM (ﬁnal
concentration) of pHT01-ΔlacI or pHT01-ΔlacI-renilla plasmid DNA
were incubated at 30 °C for three hours prior to the addition of the
luciferase assay buﬀer and substrate. Bioluminescence (480–80 nm)
was detected in cell-free reactions that expressed Renilla luciferase
from plasmid pHT01-ΔlacI-renilla and as expected control reactions
(with plasmid pHT01-ΔlacI) produced negligible bioluminescence
(Fig. 6b, Fig. 6c). These experiments were carried out in order to
demonstrate the potential applicability of B. subtilis cell-free transcrip-
tion-translation reactions for cell-free protein production and in situ
Fig. 4. Characterisation of an engineered Bacillus subtilis promoter library. (a)
Schematic displaying the sequences of engineered promoters that were derived from
PCR reactions involving degenerate primers that target the −10 and −35 boxes within the
wildtype Pgrac (σA) promoter (prWK-WT) (b) For in vitro cell-free characterisation, the
relative strength of the promoters was calculated from the rate of ﬂuorescence increase
during a phase of increasing GFPmut3b expression (20–80 min). The background
ﬂuorescence of cell-free reactions using the negative control plasmid (pHT01-ΔlacI),
were subtracted and these data were normalised to the relative strength of prWK-WT
which was denoted a relative strength of 1. For in vivo plate reader characterisation, the
relative strength of the promoters was calculated as the rate of ﬂuorescence (GFPmut3b)
per cell growth (OD600 nm) increase during a set time period (240–300 min). The
background ﬂuorescence of 2x YTP cell growth media and cells transformed with the
negative control plasmid (pHT01-ΔlacI) were subtracted and these data were normalised
to the relative strength of pWK-WT which was denoted a relative strength of 1. For in
vivo ﬂow cytometry characterisation, the ﬂuorescence (Geometric mean BL1-A; Ex.
488 nm, Em. 530/30) was measured using an Attune NxT ﬂow cytometer and were
analysed using FlowJo (vX 10.1r5) software. The background ﬂuorescence of cells
transformed with the negative control plasmid (pHT01-ΔlacI) were subtracted and these
data were normalised to the relative strength of pWK-WT which was denoted a relative
strength of 1. Error bars denote standard error of the mean.
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characterisation of enzyme performance. tableIt is likely that as cell-
free protein synthesis driven metabolic engineering approaches devel-
op the parallel characterisation of enzymes, that are encoded within
DNA libraries, may enable the rapid optimisation of biosynthetic
pathways (Dudley et al., 2015; Karim and Jewett, 2016)..
4. Conclusions
B. subtilis is an established model organism of broad importance to
microbiology, synthetic biology and industrial biotechnology.
Therefore, the development of B. subtilis cell-free transcription-trans-
lation systems are desirable since, much like existing cell-free tran-
scription-translation systems, they could be applied to several applica-
tions. Yet, despite their potential B. subtilis cell-free transcription-
translation systems have been largely neglected. Previously reported B.
subtilis cell-free transcription-translation systems were typically en-
cumbered by a range of diﬀerent factors that signiﬁcantly hindered the
accessibility of the methods used to generate them and their capabil-
ities (e.g. poor reaction dynamics and low cell-free protein production
yields) (Table 1).
Herein, we report on the development of several B. subtilis cell-free
systems that unlike previously reported methods do not require the
preparation or use of exogenous mRNAs, ribosomes, DNAse or
protease inhibitors. Consequently, we report that our method is much
more accessible and easier to carry out in a shorter time frame -
typically several batches of cell extract can be generated in just a few
days. Additionally, in contrast to previous reports, we describe the use
and improvement of a relatively more eﬃcient energy regeneration
system, based on 3-phosphoglycerate (3-PGA) and optimised concen-
trations of magnesium and potassium glutamate, that is now typically
used in E. coli cell-free transcription-translation reactions. In combi-
nation these improvements have enabled the development of an
improved B. subtilis WB800N system that is capable of robust cell-
free transcription-translation reactions that last for several hours and
can produce up to 0.8 µM GFPmut3b, which is a ~72× fold-improve-
ment when compared with a B. subtilis 168 cell-free transcription-
translation system (0.011 µM GFPmut3b). However, additional im-
provements are needed to increase B. subtilis cell-free activity to
comparable levels of recently published E. coli cell-free transcription-
translation systems (production of over 40 µM of reporter protein)
(Caschera and Noireaux, 2015b, 2014). Conversely, an examination of
developments in E. coli or other cell-free transcription systems may
provide insights into how further improvements in B. subtilis cell-free
activity may be achieved. In particular, an examination of alternative
energy sources (e.g. maltose, maltodextrin or hexametaphosphate), co-
factor regeneration systems and an analysis of the availability of the
cellular machinery (e.g. ribosomes) in cell extract batches may be the
most signiﬁcant priorities for future studies.
Whilst, further improvements in B. subtilis cell-free activity are
desirable we demonstrate the applicability of our reported B. subtilis
WB800N cell-free transcription-translation system towards regulatory
element prototyping. Essentially, we engineered several promoters,
derived from the wild-type Pgrac (σA) promoter, that display a range
of comparable in vitro and in vivo transcriptional activities. Thus, we
anticipate that these cell-free systems will be useful to applications
Fig. 5. Characterisation of a Bacillus subtilis WB800N-pHT01 cell-free transcription-
translation system for inducible gene expression. (a) Schematic depicts the generation of
B. subtilis WB800N-pHT01 cell extracts for inducible gene expression (b) Plasmid
pHT01-gfpmut3b enables IPTG inducible gfpmut3b expression within B. subtilis
WB800N-pHT01-based cell-free transcription-translation reactions. (c) Endpoint (5 h)
characterisation of IPTG induced gene expression from plasmid pHT01-gfpmut3b
(10 nM ﬁnal concentration) in B. subtilis WB800N-pHT01 cell-free transcription-
translation reactions. The background ﬂuorescence of cell-free reactions using the
negative control plasmid (pHT01), and the indicated range of IPTG were subtracted.
Error bars denote standard error of the mean. Student t-test, *P < 0.05.
Fig. 6. Characterisation of Renilla luciferase in B. subtilis WB800N cell-free reactions.
(a) Schematic depicts the cell-free expression and enzymatic activity of Renilla luciferase
within B. subtilis WB800N cell-free transcription-translation reactions. Cell-free reac-
tions including either 10 nM (ﬁnal concentration) of pHT01-ΔlacI or pHT01-ΔlacI-
renilla were incubated at 30 °C for three hours prior to the addition of the luciferase
assay buﬀer and substrate. (b) Time course analysis of Renilla luciferase activity within
Cell-fee reactions. Luminesence (480–80 nm) was measured, post-2-second delay, for
10 s using a Clariostar plate reader. (c) Integrated analysis was calculated as the
summation of luminescence, throughout the 10 s measurement cycle, for each sample.
Error bars denote standard error of the mean.
R. Kelwick et al. Metabolic Engineering xx (xxxx) xxxx–xxxx
10
such as the engineering of in vivo metabolic pathways or genetic
circuits that require characterised regulatory elements (e.g. promoters)
in order to rationally ﬁne tune gene expression. Additionally, as a step
towards future applications for B. subtilis cell-free systems, we
described the characterisation of an inducible expression system (a
precursor to genetic circuit prototyping) and we also characterised the
activity of Renilla luciferase (a model enzyme). More broadly, we
envision that these improved B. subtilis cell-free transcription-transla-
tion systems will spur a renewal in eﬀorts to continue the development
of these systems for the beneﬁt of an array of synthetic biology and
metabolic engineering applications.
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